Understand the source comparison
Best Research Peptides for CIRS Research: Mechanism Comparison
BPC-157 Mast cell stabilisation, VEGF/FGF upregulation Prevents histamine/cytokine release; repairs gut and BBB permeability 40–60% reduction in mast cell activation markers (neuroinflammation models, 2021) 200–500mcg daily subcutaneous or oral Most direct evi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Mast cell stabilisation, VEGF/FGF upregulation
- Prevents histamine/cytokine release; repairs gut and BBB permeability
- 40–60% reduction in mast cell activation markers (neuroinflammation models, 2021)
- 200–500mcg daily subcutaneous or oral
- Most direct evidence for barrier repair and mast cell control. Central CIRS mechanisms
- Thymosin Beta-4
- Nrf2-ARE activation, mitochondrial biogenesis
- Upregulates antioxidant enzymes; restores ATP synthesis capacity
- 35% improvement in mitochondrial respiration (neuroinflammatory models, 2020)
- 5–10mg subcutaneous, loading then maintenance protocols
- Strongest case for mitochondrial dysfunction. Addresses CIRS fatigue and oxidative stress
- KPV
- NF-κB nuclear translocation inhibition
- Blocks inflammatory gene transcription without immune suppression
- 50–70% reduction in cytokine expression (colitis models, 2019)
- 500mcg–2mg daily oral or subcutaneous
- Most targeted anti-inflammatory action. Stops cytokine self-perpetuation at the gene level